Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

NCT01696045 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class

Stopped Slow accrual

Conditions

Interventions

Sponsor

Bristol-Myers Squibb